ACADIA Pharmaceuticals Inc. Securities Litigation

Welcome to the ACADIA Pharmaceuticals Inc. Securities Litigation Website

ACADIA Pharmaceuticals Inc. Securities Litigation

UNITED STATES DISTRICT COURT

SOUTHERN DISTRICT OF CALIFORNIA

Case No: 15-cv-00575 BTM DHB

If you purchased or otherwise acquired publicly traded ACADIA Pharmaceuticals Inc. common stock and/or call options in the United States or on the NASDAQ Global Select Market between November 10, 2014 through and including March 11, 2015, you might be a member of the settlement class in this action entitling you to a payment in connection with a settlement of the action.

To claim your share of the Net Settlement Fund, you must submit a valid Proof of Claim and Release Form postmarked or received no later than September 16, 2017. The Notice explains the lawsuit, the Settlement, the Plan of Allocation, your legal rights, what benefits are available, who is eligible for them, and how to receive them.

SPECIAL NOTICE TO BANKS, BROKERS, AND NOMINEES

You are a nominee owner, such as brokerage firms, if you purchased or otherwise acquired ACADIA securities during the Class Period as a record owner but not as beneficial owner. Such nominees who hold or held ACADIA securities for beneficial owners who are Class Members are directed (a) to provide the Claims Administrator with lists of the names and last known addresses of the beneficial owners for whom they purchased or otherwise acquired ACADIA securities during the Class Period within 7 calendar days of receipt of the Settlement Notice, or (b) to send the Settlement Notice and Proof of Claim Form to the beneficial owners. If the nominee owner elects to send the Settlement Notice and Proof of Claim Form to the beneficial owners, the nominee owner is directed (i) to request additional copies of the Settlement Notice and Proof of Claim Form within 7 calendar days of receipt of the Settlement Notice, and (ii) to mail the Settlement Notice and Proof of Claim Form within 7 calendar days of receipt of the copies of the Settlement Notice from the Claims Administrator, and upon such mailing the nominee owner shall send a statement to the Claims Administrator confirming that the mailing was made as directed. Such nominee owners shall be reimbursed from the Settlement Fund, after receipt by the Claims Administrator of proper documentation, for the reasonable expenses of sending the Settlement Notice and Proof of Claim Form to the beneficial owners. Please send all requests to the Administrator either be email to Nominees@AcadiaSecuritiesSettlement.com or by mail to: ACADIA Pharmaceuticals Inc. Securities Litigation, c/o KCC Class Action Services, 3301 Kerner Blvd., San Rafael, CA 94901.